From the Department of Molecular Pharmacology, Stanford University, Stanford, California 94305-5174
Received for publication, September 1, 2000, and in revised form, October 5, 2000
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The c-Jun N-terminal kinases (JNKs) are members
of the mitogen-activated protein kinase family that play critical roles
in stress responses and apoptosis. We have discovered that JNK is present in Xenopus oocytes, an experimental system that
offers a variety of powerful experimental approaches to questions of protein function and regulation. Like ERK2/p42 MAPK, JNK is activated just prior to germinal vesicle breakdown during Xenopus
oocyte maturation and remains active throughout meiosis I and II.
However, unlike p42 MAPK, which is inactivated about 30 min after eggs are fertilized or parthenogenetically activated, JNK stays
constitutively active until the early gastrula stage of embryogenesis.
These findings suggest that the JNK pathway may play a role in oocyte maturation and embryogenesis. JNK was activated by microinjection of
Mos, by activation of an estrogen-inducible form of Raf, and by a
constitutively active MEK-1 (MEK R4F), indicating that the p42 MAPK
cascade can trigger JNK activation. However, the MEK inhibitor U0126
blocked progesterone-induced p42 MAPK activation but not
progesterone-induced JNK activation. Thus, progesterone can stimulate
JNK activation both through the MEK/p42 MAPK pathway and through
MEK/p42 MAPK-independent pathways. Many of the key substrates of JNKs
identified to date are transcriptional regulators. However, since
transcription is not required for germinal vesicle breakdown in
progesterone-treated oocytes or for the early embryonic cell cycles,
our findings suggest that in these contexts the JNK pathway exerts
nongenomic effects.
The Jun N-terminal kinases
(JNKs),1 also termed
stress-activated protein kinases, are a subfamily of MAP kinases
implicated in cytokine and stress responses (1-3). In mammals there
are three JNK genes, the ubiquitously expressed jnk1
and jnk2 genes and the brain-, heart-, and testis-specific
jnk3 gene (4). Each of these genes can give rise to 46- and
55-kDa forms of the JNK protein through alternative mRNA splicing
(4).
Like the ERK1/2 and p38 subfamilies of MAP kinases, the JNKs are
components of a modular MAP kinase cascade (5, 6). At the top of the
cascade is a MAP kinase kinase kinase. The MAPKKK (JNKKK)
phosphorylates and activates a MAP kinase kinase. The MAPKK (JNKK) in
turn phosphorylates and activates the MAPK (JNK). Two JNK-activating
MAPKKs have been identified, MKK4 and MKK7. These dual-specificity
protein kinases activate JNK by phosphorylating conserved Thr and Tyr
residues (Thr-Pro-Tyr) situated in the kinase activation loop. MKK4 and
MKK7 in turn can be activated by numerous MAPKKKs. The
MKK4/MKK7-activating MAPKKKs include MEKK1, MEKK2, MEKK3, MEKK4/MTK1,
MEKK5/MAPKKK5, MST/MLK2, MUK/DLK, MLK3/SPRK, TAK1, Tpl-1/2, and ASK1
(3). In addition, Ste20-related protein kinases, calmodulin kinases,
and phosphatidylinositol 3-kinases can all bring about JNK activation
(7-9). Thus, many different signaling proteins are able to feed into
the activation of the p46 JNK and p55 JNK proteins.
JNK cascades have long been suspected of mediating pro-inflammatory and
pro-apoptotic responses. Recently these ideas have been tested through
the analysis of transgenic mice with disruptions in their
jnk1, jnk2, and/or jnk3 genes or in
upstream activators (10-12). In addition, a JNK homolog has been
identified in Drosophila, allowing genetic analysis of JNK
function. These studies have provided important insights into JNK
function in morphogenesis (3, 13-16).
Here we have begun examining JNK regulation in another powerful
experimental system, Xenopus laevis oocytes, eggs, and
embryos. By virtue of their large size and natural cell cycle
synchrony, these cells have been fruitful systems for the
identification of cell cycle regulators and inducers of early
development, exploration of apoptotic pathways, and examination of
quantitative aspects of signal transduction systems. We set out to
determine whether Xenopus oocytes possess a JNK-like protein
and whether any such JNK protein was activated during oocyte maturation
or early embryogenesis. Here we show that Xenopus oocytes
express p40 JNK and p49 JNK isoforms. JNK activity increases abruptly
just prior to germinal vesicle breakdown during Xenopus
oocyte maturation, at the boundary between G2-phase and
meiotic M-phase, and remains high throughout early embryogenesis until
early gastrulation. It is possible that JNK plays an important role in
these processes and exerts its function by regulating targets other
than transcriptional regulators.
Antibodies--
Anti-JNK antibodies used were mouse monoclonal
anti-JNK2 (D2; Santa Cruz Biotechnology), rabbit polyclonal anti-JNK1
(SC571; Santa Cruz Biotechnology), and anti-JNK2 (SC572; Santa Cruz
Biotechnology) as well as anti-phospho-JNK (G7; Santa Cruz
Biotechnology). The X15 polyclonal anti-p42 MAPK antiserum was used for
immune complex kinase assays (17). Polyclonal anti-estrogen receptor
antibodies (HC-20) were obtained from Santa Cruz Biotechnology.
Recombinant Proteins--
The cDNAs for a constitutively
active, His6-tagged version of human MEK-1 (with Ser-218
replaced by Glu, Ser-222 replaced by Asp, and a deletion of amino acids
32-51, hereafter referred to as MEK R4F) and catalytically inactive
MEK-1 (with Lys-97 replaced by Met) were provided by Natalie Ahn
(University of Colorado, Boulder, CO) (18, 19). MEK proteins were
expressed in Escherichia coli and purified to homogeneity by
nickel-chelate chromatography. The cDNA for a malE-Mos fusion
protein was provided by Monica Murakami (NCI-Frederick Cancer Research
and Development Center) and George Vande Woude (Van Andel Research
Institute, Grand Rapids, MI). malE-Mos was expressed in E. coli and purified as described (20).
Isolation and Microinjection of Oocytes--
Xenopus
ovarian tissue was surgically removed, and oocytes were defolliculated
for 1-1.5 h at room temperature with 2 mg/ml collagenase and 0.5 mg/ml
polyvinylpyrrolidone in Ca2+-free modified Barth's
solution (88 mM NaCl, 1 mM KCl, 0.82 mM MgSO4, 2.4 mM
NaHCO3, 10 mM HEPES, pH 7.5). The oocytes were
then washed four times with modified Barth's solution. Stage VI
oocytes were sorted manually and incubated at 16 °C for at least
10 h in OR2 solution (82.5 mM NaCl, 2.5 mM
KCl, 1 mM CaCl2, 1 mM
Na2HPO4, 5 mM HEPES, pH 7.5)
supplemented with 1 mg/ml bovine serum albumin and 50 µg/ml
gentamicin. Immature oocytes were microinjected with MEK R4F or Mos
protein and transferred to fresh OR2 for the duration of the time
course. Ten oocytes were collected per time point, frozen on dry ice,
and stored at Isolation of Eggs, Parthenogenetic Activation, and in Vitro
Fertilization--
Female frogs were induced to lay eggs by injection
with 500 units of human chorionic gonadotropin (Sigma) and kept in egg laying buffer (0.12 M NaCl, 10 mM KCl, 24 mM NaHCO3, 8 mM MgSO4, 30 mM Tris, pH 7.6, 0.7 mM CaCl2)
for 16 h. Eggs were collected by gentle squeezing and were
immediately transferred to 0.1× MR buffer (10 mM NaCl,
0.18 mM KCl, 0.2 mM CaCl2, 0.1 mM MgCl2, 0.5 mM HEPES, pH 7.6).
For parthenogenetic activation, eggs were dejellied for 5 min in 3%
cysteine, pH 7.6, washed with 1× MR buffer (10× the concentrations
described above), and given two 1-s electrical shocks (12 V,
alternating current) (21). Testes were isolated, and in
vitro fertilization was carried out as described (22). Fertilized
eggs were dejellied in 3% cysteine, pH 7.6, for 4 min at room
temperature, transferred to 0.1× MR, and lysed at the appropriate
embryonic stages.
Lysis of Oocytes, Eggs, and Embryos--
Frozen oocytes, eggs,
and embryos were thawed rapidly and lysed by pipetting up and down in
60 µl of ice-cold extraction buffer (EB) (0.25 M sucrose,
0.1 M NaCl, 2.5 mM MgCl2, 20 mM HEPES, pH 7.2) containing 10 mM EDTA,
protease inhibitors (10 µg/ml leupeptin, 10 µg/ml pepstatin, 10 µg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride), and
phosphatase inhibitors (50 mM 2-glycerophosphate, 1 mM sodium orthovanadate, 2 µM microcystin).
Samples were clarified by centrifugation for 2.5 min in a Beckman E
microcentrifuge with a right angle rotor. Crude cytoplasm was collected
and processed for immunoblotting or kinase assays, as described below.
Immunoblotting--
Aliquots of oocyte, egg, or embryo lysates
were added to 0.2 volumes of 6× Laemmli sample buffer. Samples were
separated on 10% SDS-polyacrylamide gels (bisacrylamide:acrylamide,
100:1) and the proteins transferred to PVDF blotting membrane (Amersham Pharmacia Biotech). The membrane was blocked with 3% nonfat milk in
Tris-buffered saline (150 mM NaCl, 20 mM Tris,
pH 7.6) and incubated with primary antibodies. Blots were washed five
times with TBS, 0.5% Tween 20 and probed with an peroxidase-conjugated secondary antibody for detection by enhanced chemiluminescence (ECL-Plus, Amersham Pharmacia Biotech). For reprobing, blots were stripped by incubation with 100 mM Tris-HCl, pH 7.4, 100 mM 2-mercaptoethanol, and 2% SDS at 70 °C for 40 min.
Jun Kinase Assay--
Jun kinase assays were performed as
described (23). Crude oocyte, egg, or embryo cytoplasm was diluted 1:1
in EB and pre-cleared with 20 µl of glutathione-Sepharose beads
(Amersham Pharmacia Biotech) for 1 h at 4 °C with moderate
shaking. Lysates were incubated with glutathione
S-transferase GST-c-Jun-(1-79) fusion protein (hereafter
denoted GST-Jun) immobilized on glutathione-Sepharose beads. After
3 h at 4 °C, the beads were washed three times with 50 mM HEPES, pH 7.5, 150 mM NaCl, 1% Triton
X-100, 1 mM EDTA, 10% glycerol, 10 mM sodium
pyrophosphate, 2 mM sodium orthovanadate, 10 mM
sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, and 10 µg/ml aprotinin (24) and once with 0.4 ml of kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 200 µM sodium
orthovanadate). The bound JNK activity was detected by the addition of
1 µCi of [ Immunocomplex in Vitro Kinase Assays--
Xenopus p42
MAPK was immunoprecipitated from lysates using polyclonal antibody X15.
Crude cytoplasmic lysates were diluted 1:1 in EB and precleared with 20 ml of protein A-Sepharose (Sigma). After 3 h at 4 °C at
moderate shaking, immunoprecipitates were washed three times with 50 mM HEPES, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 10 mM sodium
pyrophosphate, 2 mM sodium orthovanadate, 10 mM
sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, and 10 µg/ml aprotinin and washed once with 1 ml of kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 200 µM sodium
orthovanadate). Subsequently, kinase reactions were performed in 40 µl of kinase buffer supplemented with 4 mg/ml myelin basic protein
(MBP) (Sigma), 50 µM ATP, and 1 mCi of
[
Xenopus Oocytes Express p40 JNK and p49 JNK Isoforms--
We
subjected lysates from G2- and M-phase oocytes to
immunoblotting with a JNK-specific monoclonal antibody. We detected two putative JNK bands, with apparent molecular masses of 40 and 49 kDa
(Fig. 1A, left panel).
Vertebrate JNKs bind tightly to the N terminus of c-Jun, which contains
the residues (Ser-63 and Ser-73) that JNK phosphorylates (23). A fusion
of GST with the first 79 amino acids of c-Jun can therefore be used as
an affinity reagent to precipitate JNK protein and activity. We
subjected Xenopus oocyte lysates to precipitation with
GST-Jun, and we looked for JNK protein by immunoblotting. As shown in
Fig. 1A (right panel), GST-Jun brought down the
p40 and p49 bands seen in JNK immunoblots of whole lysates. Control GST
beads did not bring down p40 or p49. This finding supports the
identification of p40 and p49 as authentic JNKs, possibly corresponding
to the p46 and p54 isoforms expressed in mammalian cells.
Immunoprecipitation of JNK Activity from M-phase Oocytes--
Next
we examined whether JNK activity differed in G2-phase
immature oocytes and M-phase mature oocytes. We subjected JNKs to
precipitation with nonimmune serum, GST-Jun beads, or four different
JNK antisera, one of which (G7) is known not to support immune complex
kinase activity. As shown in Fig. 1B, two of the JNK
antisera (SC571 and SC572) and the GST-Jun beads brought down substantial levels of Jun kinase activity from M-phase oocytes. Jun
kinase activity was not detected in the nonimmune serum precipitates or
in the D2 or G7 precipitates (Fig. 1B). None of the reagents brought down significant levels of Jun kinase activity from
G2-phase oocytes (Fig. 1B). These findings
further confirm that JNK is present in oocytes and indicate that JNK
becomes activated during Xenopus oocyte maturation.
Time Course of JNK Activation during Xenopus Oocyte
Maturation--
Next we examined the time course of
progesterone-induced JNK activation in detail. JNK activity increased
markedly just prior to GVBD, as did p42 MAPK activity (Fig.
2). Like p42 MAPK activity, JNK activity
remained high throughout meiosis I and meiosis II. This pattern of JNK
activation suggests a possible role for the JNK signaling pathway in
oocyte maturation and the G2/M cell cycle transition.
JNK Activity during the First Mitotic Cell Cycle--
To examine
JNK activity during the first mitotic cell cycle, we obtained
dejellied, M-phase-arrested unfertilized Xenopus eggs and
released them from their arrest with an electric shock. We then
followed JNK activity and p42 MAPK activity. As shown in Fig.
3, p42 MAPK activity fell by 30 min
post-shock and then remained low during the first mitotic cycle. In
contrast, JNK activity was high throughout the entire time course (Fig.
3). Similar results were obtained with calcium ionophore-treated eggs (data not shown). These findings show that there are important differences between JNK regulation and p42 MAPK regulation in the
Xenopus cell cycles.
JNK Activity during Embryogenesis--
We fertilized
Xenopus eggs in vitro, dejellied them, and then
collected samples at various stages of embryogenesis. As shown in Fig.
4, JNK activity was high during the rapid
early embryonic cell cycles and the blastula stage and then decreased
to basal levels at the early gastrula stage. In contrast, p42 MAPK
activity fell before the first post-fertilization sample was taken (45 min after fertilization) and remained low throughout embryogenesis. These findings again point out the differences between JNK regulation and p42 MAPK regulation and suggest that JNK may play an important role
in the pre-gastrula stage embryo.
Activation of Xenopus JNK by Mos,
As shown in Fig. 5A, injection
of Mos (yielding an estimated intra-oocyte concentration of 200 nM) brought about activation of both p42 MAPK and JNK and
also induced GVBD. No JNK activation, p42 MAPK activation, or GVBD was
seen in mock-injected controls (data not shown).
We also examined the effects of Raf activation on JNK activity.
Although both Raf and Mos can function as MAPKKKs, their hierarchy within the p42 MAPK cascade is less clear, and the exact position of
Raf within the p42 MAPK cascade in Xenopus oocytes is
controversial. Nevertheless, active forms of Raf can be used as a way
of activating the MAPK cascade and inducing GVBD in oocytes in the
absence of progesterone. We therefore examined whether activation of
Raf-1 causes JNK activation.
We microinjected oocytes with synthetic mRNA encoding a chimera of
an oncogenic form of human c-Raf-1 (
Finally, we examined the effects of constitutively active MEK-1 (MEK
R4F) on JNK activity. Constitutively active forms of MEK-1 induce p42
MAPK activation and maturation when injected into oocytes (28, 29). As
shown in Fig. 5C, concentrations of MEK R4F that were
sufficient to cause p42 MAPK activation and GVBD also caused JNK
activation. Microinjection of kinase-minus MEK-1 had no effect on JNK
activity (data not shown).
In summary, activation of the p42 MAPK cascade by either Mos,
Xenopus JNK Activation in the Absence of p42 MAPK
Activation--
By having shown that the JNK cascade can be activated
downstream of the p42 MAPK cascade, we next examined whether activation of p42 MAPK was required for JNK activation. First we examined whether
hyperosmolar stress, which is known to activate JNKs in other cell
types, would activate JNK and p42 MAPK in oocytes. Hyperosmolar
sorbitol (0.5 M) caused marked activation of JNK (Fig.
6A) but no detectable
activation of p42 MAPK (Fig. 6B). Thus p42 MAPK activation
is not an absolute prerequisite for JNK activation in oocytes.
We next examined whether p42 MAPK activation was required for
progesterone-induced JNK activation. We treated oocytes with progesterone in the presence or absence of U0126, an inhibitor of
MEK-1. As shown in Fig. 7, U0126
effectively blocked progesterone-induced p42 MAPK activation but had no
apparent effect on progesterone-induced JNK activation. Thus, although
activation of the p42 MAPK cascade can bring about JNK activation, p42
MAPK activation is not required for JNK activation. Because the
accumulation of Mos not only stimulates p42 MAPK activation, but also
depends upon p42 MAPK activation (29-31), U0126 blocks Mos
accumulation as well as MEK-1 and p42 MAPK activation (data not shown).
Thus, there must be a pathway from the progesterone receptor to the JNK
cascade that requires little or no support from Mos, MEK-1, or p42
MAPK.
Inhibition of the Mos/MEK-1/p42 MAPK cascade has been reported to
either block maturation or delay it (29, 32-37). In the experiment
shown in Fig. 7, none of the U0126-treated oocytes matured, even after
20 h of progesterone treatment, despite the fact that their JNK
was fully activated. This finding demonstrates that full JNK activation
is not sufficient to ensure maturation when p42 MAPK activation is blocked.
JNK Activation in "Unhealthy" Oocytes--
Oocytes in culture
sometimes degenerate, developing some mottling of the pigment in the
animal hemisphere (Fig. 8, A
and B). Ultimately these oocytes adopt the "gray
puffball" phenotype and die. Since JNKs have been implicated in
apoptosis in other systems, we examined JNK activity in mottled,
unhealthy oocytes. As shown in Fig. 8C, unhealthy
oocytes showed an elevated basal JNK activity but not an elevated basal
p42 MAPK activity. Their JNK and p42 MAPK activities increased in
response to progesterone, although the p42 MAPK activation was smaller
than that seen in healthy oocytes (Fig. 8C). These findings
raise the possibility that the JNK pathway may contribute to apoptosis
in Xenopus oocytes.
In this study we have shown that Xenopus oocytes, eggs,
and early embryos express 40- and 49-kDa isoforms of JNK, which we suspect correspond to the 46- and 54-kDa isoforms of mammalian JNKs.
Both of the bands were recognized by anti-JNK1 and anti-JNK2 antibodies. Thus it is not certain whether Xenopus oocytes
express four different JNK proteins (long and short splice variants of both JNK1 and JNK2) or just two JNK proteins (long and short) that
cross-react with the anti-JNK1 and anti-JNK2 sera.
Xenopus JNK is activated just prior to GVBD during oocyte
maturation, at about the same time as the activation of p42 MAPK. Like
p42 MAPK, JNK stays active throughout meiosis I and meiosis II. But
unlike p42 MAPK (and Cdc2), JNK remains active after fertilization. JNK
activity is high throughout the period of rapid embryonic cleavages
(fertilization through the midblastula transition) and then falls at
the early gastrula stage. The decline in JNK activity occurs shortly
after the commencement of zygotic transcription (38).
Stimuli that directly impinge upon the MAPK cascade, Mos, Progesterone can cause JNK activation even when Mos accumulation, MEK-1
activation, and p42 MAPK activation are inhibited by U0126. Thus, there
is also a pathway from the progesterone receptor to the JNK cascade
that does not depend upon input from Mos, MEK-1, or p42 MAPK. Likewise,
hyperosmolar stress activates JNK without activating p42 MAPK. The
Xenopus homologs of MKK4 or MKK7 could be likely
participants in the p42 MAPK-independent JNK activation pathway.
Fig. 9 schematically summarizes our
current understanding of the Mos/MEK-1/p42 MAPK pathway and the JNK
cascade in oocytes. Important open questions include the exact
identities of the p40 and p49 JNK proteins, the identities of the
upstream kinases in the JNK cascade, the connections between the
Mos/MEK-1/p42 MAPK cascade and the JNK cascade, and the connections
between the progesterone receptor and the JNK cascade.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
80 °C.
-32P]ATP. The reaction was terminated
after 20 min at 30 °C, and the products were resolved by SDS-PAGE.
The gels were transferred to PVDF membranes (Hybond; Amersham Pharmacia
Biotech) and the incorporation of [32P]phosphate into
GST-Jun was visualized by autoradiography.
-32P]ATP for 20 min at 30 °C. Reactions were
stopped by addition of 8 µl of 6× Laemmli buffer and subjected to
gel electrophoresis on 12.5% gels. Gels were transferred to PVDF
(Hybond; Amersham Pharmacia Biotech) membranes. Phosphorylated
substrate was detected by autoradiography on Kodak Biomax MS film.
Raf-DD:ER Expression, Immunoprecipitation, and Activity
Assay--
The cDNA for a human Raf-estrogen receptor chimera,
designated
Raf-DD:ER, was a generous gift from M. McMahon. The Raf
portion of the chimera has been activated by deletion of the N terminus and substitution of aspartate residues at Tyr-340 and -341 (25). The
estrogen receptor portion of the chimera makes the Raf activity regulatable by estradiol.
Raf-DD:ER was cloned into pSP64 poly(A) (Promega), and mRNA was generated by in vitro
transcription (Ambion). Stage VI oocytes were collected and injected
with 50 ng of
Raf-DD:ER mRNA and incubated overnight to allow
protein expression. Injected oocytes were incubated with 1 µM estradiol to activate the
Raf-DD:ER.
Raf-DD:ER-expressing oocytes were lysed in 300 µl of 20 mM Tris, pH 7.9, 137 mM NaCl, 5 mM
EDTA, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride,
1 mM sodium orthovanadate, 1 mM aprotinin, 1 mM leupeptin, 1 µM pepstatin A, 1 mM EGTA, 10 mM NaF, and 100 µM
-glycerophosphate. Cleared lysates were incubated with 30 µl of
protein A-Sepharose (precoated with anti-estrogen receptor antibody) at
4 °C for 2 h, and washed once with lysis buffer and once with
kinase buffer (25 mM HEPES, pH 7.4, 10 mM
MgCl2, 1 mM MnCl2, 1 mM
dithiothreitol). Samples were then incubated at 30 °C for 30 min
with kinase buffer supplemented with 1 µM ATP, 20 µCi
of [
-32P]ATP, and 50 ng of purified recombinant MEK
protein. The reactions were denatured by boiling in sample buffer and
electrophoresed on a 10% SDS-PAGE. The gel was transferred to a PVDF
membrane and exposed to x-ray film (Kodak Biomax MS) to detect
incorporated radioactivity.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (57K):
[in a new window]
Fig. 1.
JNK expression and activity in
Xenopus oocytes. A, JNK immunoblots.
Lysates of 10 unstimulated (G2-phase, Dumont Stage VI) or
progesterone-stimulated (M-phase) oocytes were either directly
separated on a 10% polyacrylamide gel (left panel) or were
subjected to pull-down with control GST beads or GST-Jun followed by
electrophoresis (right panel). Proteins were transferred to
PVDF membranes and immunoblotted with monoclonal anti-JNK antibodies
(D2; Santa Cruz Biotechnolgy). B, JNK precipitation and
kinase assay. Lysates of G2- and M-phase oocytes (10 each)
were subjected to immunoprecipitation with a nonimmune serum or an
anti-JNK serum, as indicated. Immune complex kinase assays were
performed using GST-Jun as a substrate. As a positive control, lysates
were incubated with immobilized GST-Jun. Samples were separated on
12.5% polyacrylamide gels and transferred to PVDF membranes.
Incorporated radioactivity was detected by autoradiography.
View larger version (35K):
[in a new window]
Fig. 2.
Time course of progesterone-induced JNK and
p42 MAPK activation. Dumont Stage VI oocytes were stimulated with
progesterone (6 µM) and frozen down at the times
indicated. Lysates of 10 oocytes were split. A portion (75%) of the
lysate was incubated with immobilized GST-Jun (upper panel)
for JNK kinase assay, and the remainder (25%) was incubated with
protein A-bound p42 MAPK antibodies (15×) for p42 MAPK activity assay
(middle panel). MBP was used as a substrate for the p42 MAPK
kinase assay. Kinase reactions were separated by PAGE, transferred, and
autoradiographed. GVBD was measured by appearance of a white
dot and by manually dissecting the oocyte (lower
panel). Similar results were obtained in three independent
experiments.
View larger version (31K):
[in a new window]
Fig. 3.
JNK activity and p42 MAPK activity during the
first mitotic cell cycle in parthenogenetic activated
Xenopus eggs. Eggs were activated by electric
shock and lysed at the indicated time points. Lysates split for JNK
kinase assays and p42 MAPK assays, as described in Fig. 2.
Phosphorylated substrates, GST-Jun and MBP, were detected by
autoradiography. Similar results were obtained in three independent
experiments.
View larger version (38K):
[in a new window]
Fig. 4.
JNK and p42 MAPK activities during
embryogenesis in X. laevis. Eggs were fertilized
in vitro and lysed at the indicated stages of development.
Lysates were split for JNK and p42 MAPK activity assays, as described
in Fig. 2. Kinase reactions were performed, separated on 12.5%
polyacrylamide gels, and transferred to PVDF membranes. Phosphorylated
substrates were detected by autoradiography. Results represent data
from three independent experiments and three different frogs.
Raf-DD:ER, and MEK
R4F--
As described above (see Fig. 2), Xenopus JNK and
p42 MAPK are activated at about the same time during oocyte maturation.
This raises the possibility that there may be some connection between the two pathways. To explore this possibility, we microinjected oocytes
with various proteins or mRNAs that could activate the p42 MAPK
cascade without triggering the most proximal events of progesterone
signaling (such as the very rapid progesterone-induced inhibition of
adenylyl cyclase) (26).
View larger version (38K):
[in a new window]
Fig. 5.
Activation of Xenopus JNK
and p42 MAPK by Mos, Raf-DD:ER, and MEK
R4F. A, activation of JNK and p42 MAPK by Mos.
Stage VI oocytes were microinjected with 50 nl of Mos protein. Assuming
the volume of an oocyte to be 1 µl, the final concentration of Mos
was 200 nM. Oocytes were lysed either immediately or after
6 or 10 h. Lysates were subjected to JNK kinase and p42 MAPK
assays as described in Fig. 2. Reactions were loaded on 12.5%
polyacrylamide gels and transferred to PVDF membranes. Phosphorylated
GST-Jun and MBP were detected by autoradiography. B,
activation of JNK and p42 MAPK by
Raf-DD:ER. Stage VI oocytes were
injected with 50 ng of
Raf-DD:ER mRNA, and the oocytes were
incubated overnight to allow protein expression. Raf was activated by
addition of 1 µM estradiol. Lysates were subjected to
immunoprecipitation with an anti-estrogen receptor antibody, and Raf
activity was assessed by incubation with [
-32P]ATP and
purified recombinant GST-MEK. Lysates were also subjected to JNK kinase
and p42 MAPK assays as described in Fig. 2. Phosphorylated GST-MEK,
GST-Jun, and MBP were detected by autoradiography. C,
activation of JNK and p42 MAPK by MEK R4F. Oocytes were microinjected
with 50 nl of constitutive active MEK (MEK R4F) protein at various
dilutions. The final concentrations of MEK assume a volume of 1 µl/oocyte. Oocytes were lysed 4 h after injection. GVBD was
measured by appearance of a white dot and was first observed
3 h after injection. Lysates were used for JNK kinase (upper
panel) and p42 MAPK assays (lower panel), as described
in Fig. 2. Results are representative of three independent
experiments.
Raf-1 DD) fused to the
hormone-binding domain of the human estrogen receptor (hereafter denoted
Raf-DD:ER) (25). After allowing protein expression overnight,
Raf-DD:ER was activated by the addition of estradiol. Note that unlike progesterone, estradiol does not initiate maturation by itself (27). Estradiol treatment caused the activation of
Raf-DD:ER, p42 MAPK, and JNK and brought about GVBD (Fig.
5B). The extent of p42 MAPK and JNK activation seen in the
mature estradiol-treated oocytes was similar to that seen in
progesterone-treated oocytes (Fig. 5B). Estradiol had
no effect on JNK activity, p42 MAPK activity, or GVBD in oocytes that
were not expressing
Raf-DD:ER (data not shown). Thus, both Mos and
Raf are capable of activating JNK in Xenopus oocytes.
Raf-DD:ER, or MEK-R4F caused activation of JNK. Thus, in
Xenopus oocytes, JNK can be activated downstream of the
Mos/MEK/p42 MAPK cascade.
View larger version (38K):
[in a new window]
Fig. 6.
Hyperosmolar stress induced by
sorbitol activates JNK but not p42 MAPK. Dumont Stage VI oocytes
were either left untreated, stimulated with progesterone (6 µM), or treated with 0.5 M sorbitol. Lysates
were subjected to JNK (A) and p42 MAPK (B)
assays, as described in Fig. 2. After transfer to PVDF membranes,
incorporated radioactivity was detected by autoradiography. Results
represent data of three independent experiments.
View larger version (31K):
[in a new window]
Fig. 7.
Inhibition of MEK-1 does not prevent
progesterone-induced JNK activation. Stage VI oocytes were
pretreated for 1 h with the 50 µM U0126 or with an
equal volume of Me2SO (DMSO) as a
control. Unstimulated and progesterone-stimulated oocytes were lysed,
split, and used for JNK and p42 MAPK assays as described in Fig. 2.
Phosphorylated GST-Jun and MBP were detected by autoradiography. GVBD
was observed only in the progesterone- and Me2SO-treated
control oocytes, and a white dot appeared 3 h after
progesterone stimulation. U0126 completely blocked progesterone-induced
GVBD in this experiment. Results represent similar data of three
independent experiments.
View larger version (86K):
[in a new window]
Fig. 8.
JNK activation in degenerating, unhealthy
oocytes. Regular, healthy, oocytes (A) were compared
with unhealthy oocytes (B), which showed early signs of
degeneration and which had a lighter color and mottling of the pigment
in the animal hemisphere. Ten oocytes of either kind were stimulated
with progesterone for 3 h or left untreated. After lysis, JNK
kinase and p42 MAPK assays were performed as described in Fig. 2. After
transfer to PVDF membranes, phosphorylated substrates were
detected by autoradiography (C).
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Raf-DD:ER,
and MEK R4F, cause activation of JNK. In principle this could be due to
the direct activation of JNK by endogenous MEK-1 (in the case of Mos
and
Raf-DD:ER) or by MEK R4F. However, in our hands MEK R4F does not
phosphorylate immunoprecipitated JNK or GST-Jun-precipitated JNK
in vitro (data not shown), and in general MEK-1 proteins
appear to be highly specific for p42 and p44 MAPK. Therefore we favor
the hypothesis that a more indirect pathway connects the MAP kinase
cascade to the JNK cascade.
View larger version (22K):
[in a new window]
Fig. 9.
Model for the JNK signaling pathway, and its
interplay with the Mos/MEK-1/p42 MAPK pathway, in X. laevis
oocytes and eggs.
Possible JNK Functions-- Another important open question is what function the JNK pathway plays in oocyte maturation and embryogenesis. There are many possibilities; however, it seems likely that whatever the function, it will not depend upon the regulation of transcription factors by JNK, since oocyte maturation and early embryogenesis can proceed in the absence of transcription. Here we shall discuss two particular hypotheses that are suggested by the timing of JNK activation and inactivation.
Regulation of Apoptosis?--
JNKs have been implicated in
apoptosis in a variety of cell types. Analysis of hippocampal neurons
from transgenic mice with disruptions of their jnk3
genes has supported a role for JNK3 in excitotoxin-induced neuronal
apoptosis (39). Similarly, analysis of embryonic fibroblasts from
transgenic mice with disruptions of their jnk1 and
jnk2 genes has supported a role for JNKs in UV-stimulated
apoptosis upstream of cytochrome c release from the
mitochondria (11). However, JNKs have also been suggested as inhibitors
of apoptosis. For example, MEKK1(/
) embryonic stem cells fail to
activate their JNK in response to hyperosmolarity and microtubule
disruption, yet they exhibit a greater apoptotic response to these
stresses (40). Further clarification of the roles of JNKs in apoptosis
is clearly warranted.
Mature Xenopus oocytes and embryos up to the early gastrula stage, the stages when JNK is active, respond in an unusual way to cell cycle perturbations. Early embryos lack the normal checkpoints that make the initiation of mitosis contingent upon DNA replication and the metaphase/anaphase transition contingent upon successful alignment of the chromosomes at the metaphase plate (41, 42). The embryo has developed a simpler strategy for dealing with cell cycle perturbations; rather than arresting and trying to correct problems in response to cell cycle perturbants, the embryo commits to carrying out apoptosis (43-46). The apoptotic program is then executed just after the mid-blastula transition, at the early gastrula stage.
At the mid-blastula transition, the cell cycle slows down and gap phases begin to occur. Then, at the early gastrula stage, when JNK becomes inactive, the embryo switches strategies for responding to cell cycle perturbants, rather than immediately committing to apoptosis, the post-mid-blastula transition embryo initiates a cell cycle arrest and tries to correct the damage.
Thus, the times when JNK is active during oocyte maturation and embryogenesis are also the times when the embryo is particularly prone to undergoing apoptosis. It will be of interest to determine whether and how the JNK activation contributes to the apoptotic response.
Regulation of Cyclin B2 Localization?-- Nearly 10 years ago, Hunt and coworkers (47) showed that cyclin B2 undergoes a mobility shift when oocytes undergo maturation and that this mobility shift depends upon the phosphorylation of Ser-90, which is situated next to a proline residue (SP). They also showed that at least two distinct kinase activities that can phosphorylate the N terminus of cyclin B2 become activated at about the time of germinal vesicle breakdown. The first kinase activity phosphorylated Ser-90; this kinase remained active until about 30 min after fertilization. The second kinase activity phosphorylated other sites in the N terminus of cyclin B2 and remained active throughout the first mitotic cell cycles. Neither of these activities appeared to be Cdc2 or p42 MAPK (47). Initial attempts were made to purify one or both of these activities. However, at the time it was unclear what the function of cyclin B2 phosphorylation might be, and so far none of these activities has been purified.
Subsequent work has shown that the N terminus of cyclin B1 contains a nuclear export sequence and that phosphorylation of residues near this nuclear export sequence is critical for nuclear accumulation of Cdc2/cyclin B1 and for the biological activity of Cdc2/cyclin B1 (48-50). The same appears to be true for cyclin B2 (51). Thus, the identification of the cyclin B2 N-terminal kinases is of high importance. Given the time course of JNK activity after parthenogenetic activation or fertilization of Xenopus eggs (Figs. 3 and 4), and given the fact that JNKs phosphorylate SP/TP residues, JNK is a candidate for the second cyclin kinase activity, the one that phosphorylates sites other than Ser-90 in the N terminus of cyclin B2. It will therefore be interesting to determine whether JNK can phosphorylate cyclin B2 in vitro and whether cyclin B2 phosphorylation in extracts depends upon JNK function.
The use of gain-of-function JNK mutations and JNK inhibitors will help
to evaluate the role of the JNK signaling pathways in oocyte
maturation, cell cycle progression, and embryogenesis. Moreover, these
tools will clarify whether JNK plays a positive or negative role in
apoptosis, the ultimate cell fate of many oocytes and eggs.
![]() |
ACKNOWLEDGEMENTS |
---|
We are grateful to N. Ahn, M. Murakami, M. McMahon, A. Ullrich, and G. Vande Woude for providing plasmids; J. Baker for help with the embryos; R. Bhatt and J. Yoon for purification of MEK proteins; and M. Sohaskey, J. Besser, and D. Schechtman for discussions and critical reading of the manuscript.
![]() |
FOOTNOTES |
---|
* This work was supported by National Institutes of Health Grant GM46383 and a Deutsche Forschungsgemeinschaft Postdoctoral Fellowship.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Molecular
Pharmacology, Stanford University, 269 West Campus Dr., Stanford, CA
94305-5174. Tel.: 650-725-0765; Fax: 650-723-2253; E-mail: ferrell@cmgm.stanford.edu.
Published, JBC Papers in Press, October 11, 2000, DOI 10.1074/jbc.M008050200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MAPKK, MAPK kinase; MAPKKK, MAPK kinase kinase; MEK, MAPK/extracellular signal-regulated kinase kinase; MAP, mitogen-activated protein; PVDF, polyvinylidene difluoride; PAGE, polyacrylamide gel electrophoresis; GST, glutathione S-transferase; GVBD, germinal vesicle breakdown; MBP, myelin basic protein.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., and Woodgett, J. R. (1994) Nature 369, 156-160[CrossRef][Medline] [Order article via Infotrieve] |
2. | Tibbles, L. A., and Woodgett, J. R. (1999) Cell. Mol. Life Sci. 55, 1230-1254[CrossRef][Medline] [Order article via Infotrieve] |
3. | Ip, Y. T., and Davis, R. J. (1998) Curr. Opin. Cell Biol. 10, 205-219[CrossRef][Medline] [Order article via Infotrieve] |
4. | Gupta, S., Barrett, T., Whitmarsh, A. J., Cavanagh, J., Sluss, H. K., Derijard, B., and Davis, R. J. (1996) EMBO J. 15, 2760-2770[Abstract] |
5. | Robinson, M. J., and Cobb, M. H. (1997) Curr. Opin. Cell Biol. 9, 180-186[CrossRef][Medline] [Order article via Infotrieve] |
6. | Lewis, T. S., Shapiro, P. S., and Ahn, N. G. (1998) Adv. Cancer Res. 74, 49-139[Medline] [Order article via Infotrieve] |
7. |
Polverino, A.,
Frost, J.,
Yang, P.,
Hutchison, M.,
Neiman, A. M.,
Cobb, M. H.,
and Marcus, S.
(1995)
J. Biol. Chem.
270,
26067-26070 |
8. |
Enslen, H.,
Tokumitsu, H.,
Stork, P. J.,
Davis, R. J.,
and Soderling, T. R.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10803-10808 |
9. | Klippel, A., Reinhard, C., Kavanaugh, W. M., Apell, G., Escobedo, M. A., and Williams, L. T. (1996) Mol. Cell. Biol. 16, 4117-4127[Abstract] |
10. | Dong, C., Yang, D. D., Tournier, C., Whitmarsh, A. J., Xu, J., Davis, R. J., and Flavell, R. A. (2000) Nature 405, 91-94[CrossRef][Medline] [Order article via Infotrieve] |
11. |
Tournier, C.,
Hess, P.,
Yang, D. D.,
Xu, J.,
Turner, T. K.,
Nimnual, A.,
Bar-Sagi, D.,
Jones, S. N.,
Flavell, R. A.,
and Davis, R. J.
(2000)
Science
288,
870-874 |
12. |
Lu, H. T.,
Yang, D. D.,
Wysk, M.,
Gatti, E.,
Mellman, I.,
Davis, R. J.,
and Flavell, R. A.
(1999)
EMBO J.
18,
1845-1857 |
13. | Stronach, B. E., and Perrimon, N. (1999) Oncogene 18, 6172-6182[CrossRef][Medline] [Order article via Infotrieve] |
14. | Noselli, S., and Agnes, F. (1999) Curr. Opin. Genet. & Dev. 9, 466-472[CrossRef][Medline] [Order article via Infotrieve] |
15. | Kockel, L., Zeitlinger, J., Staszewski, L. M., Mlodzik, M., and Bohmann, D. (1997) Genes Dev. 11, 1748-1758[Abstract] |
16. | Goberdhan, D. C., and Wilson, C. (1998) BioEssays 20, 1009-1019[CrossRef][Medline] [Order article via Infotrieve] |
17. | Hsiao, K.-M., Chou, S.-Y., Shih, S.-J., and Ferrell, J. E., Jr. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5480-5484[Abstract] |
18. | Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., and Ahn, N. G. (1994) Science 265, 966-970[Medline] [Order article via Infotrieve] |
19. | Mansour, S. J., Candia, J. M., Matsuura, J. E., Manning, M. C., and Ahn, N. G. (1996) Biochemistry 35, 15529-15536[CrossRef][Medline] [Order article via Infotrieve] |
20. | Yew, N., Mellini, M. L., and Vande Woude, G. F. (1992) Nature 355, 649-652[CrossRef][Medline] [Order article via Infotrieve] |
21. | Murray, A. W. (1991) Methods Cell Biol. 36, 581-605[Medline] [Order article via Infotrieve] |
22. | Newport, J., and Kirschner, M. (1982) Cell 30, 675-686[Medline] [Order article via Infotrieve] |
23. | Hibi, M., Lin, A., Smeal, T., Minden, A., and Karin, M. (1993) Genes Dev. 7, 2135-2148[Abstract] |
24. |
Bagowski, C. P.,
Stein-Gerlach, M.,
Choidas, A.,
and Ullrich, A.
(1999)
EMBO J.
18,
5567-5576 |
25. | Bosch, E., Cherwinski, H., Peterson, D., and McMahon, M. (1997) Oncogene 15, 1021-1033[CrossRef][Medline] [Order article via Infotrieve] |
26. | Ferrell, J. E., Jr. (1999) BioEssays 21, 833-842[CrossRef][Medline] [Order article via Infotrieve] |
27. | Baulieu, E. E., Godeau, F., Schorderet, M., and Schorderet-Slatkine, S. (1978) Nature 275, 593-598[Medline] [Order article via Infotrieve] |
28. | Huang, W., Kessler, D. S., and Erikson, R. L. (1995) Mol. Biol. Cell 6, 237-245[Abstract] |
29. |
Gotoh, Y.,
Masuyama, N.,
Dell, K.,
Shirakabe, K.,
and Nishida, E.
(1995)
J. Biol. Chem.
270,
25898-25904 |
30. | Matten, W. T., Copeland, T. D., Ahn, N. G., and Vande Woude, G. F. (1996) Dev. Biol. 179, 485-492[CrossRef][Medline] [Order article via Infotrieve] |
31. | Roy, L. M., Haccard, O., Izumi, T., Lattes, B. G., Lewellyn, A. L., and Maller, J. L. (1996) Oncogene 12, 2203-2211[Medline] [Order article via Infotrieve] |
32. | Cross, D. A., and Smythe, C. (1998) Exp. Cell Res. 241, 12-22[CrossRef][Medline] [Order article via Infotrieve] |
33. | Gross, S. D., Schwab, M. S., Taieb, F. E., Lewellyn, A. L., Qian, Y. W., and Maller, J. L. (2000) Curr. Biol. 10, 430-438[CrossRef][Medline] [Order article via Infotrieve] |
34. |
Fisher, D. L.,
Brassac, T.,
Galas, S.,
and Doree, M.
(1999)
Development
126,
4537-4546 |
35. | Fabian, J. R., Morrison, D. K., and Daar, I. O. (1993) J. Cell Biol. 122, 645-652[Abstract] |
36. | Muslin, A. J., MacNicol, A. M., and Williams, L. T. (1993) Mol. Cell. Biol. 13, 4197-4202[Abstract] |
37. | Kosako, H., Gotoh, Y., and Nishida, E. (1994) EMBO J. 13, 2131-2138[Abstract] |
38. | Newport, J., and Kirschner, M. (1982) Cell 30, 687-696[Medline] [Order article via Infotrieve] |
39. | Yang, D. D., Kuan, C. Y., Whitmarsh, A. J., Rincon, M., Zheng, T. S., Davis, R. J., Rakic, P., and Flavell, R. A. (1997) Nature 389, 865-870[CrossRef][Medline] [Order article via Infotrieve] |
40. |
Yujiri, T.,
Sather, S.,
Fanger, G. R.,
and Johnson, G. L.
(1998)
Science
282,
1911-1914 |
41. | Dasso, M., and Newport, J. W. (1990) Cell 61, 811-823[Medline] [Order article via Infotrieve] |
42. | Minshull, J., Sun, H., Tonks, N. K., and Murray, A. W. (1994) Cell 79, 475-486[Medline] [Order article via Infotrieve] |
43. | Hensey, C., and Gautier, J. (1997) Mech. Dev. 69, 183-195[CrossRef][Medline] [Order article via Infotrieve] |
44. |
Stack, J. H.,
and Newport, J. W.
(1997)
Development
124,
3185-3195 |
45. | Anderson, J. A., Lewellyn, A. L., and Maller, J. L. (1997) Mol. Biol. Cell 8, 1195-1206[Abstract] |
46. | Sible, J. C., Anderson, J. A., Lewellyn, A. L., and Maller, J. L. (1997) Dev. Biol. 189, 335-346[CrossRef][Medline] [Order article via Infotrieve] |
47. | Kobayashi, H., Golsteyn, R., Poon, R., Stewart, E., Gannon, J., Minshull, J., Smith, R., and Hunt, T. (1991) Cold Spring Harbor Symp. Quant. Biol. 56, 437-447[Medline] [Order article via Infotrieve] |
48. | Pines, J., and Hunter, T. (1994) EMBO J. 13, 3772-3781[Abstract] |
49. |
Yang, J.,
Bardes, E. S. G.,
Moore, J. D.,
Brennan, J.,
Powers, M. A.,
and Kornbluth, S.
(1998)
Genes Dev.
12,
2131-2143 |
50. | Hagting, A., Jackman, M., Simpson, K., and Pines, J. (1999) Curr. Biol. 9, 680-689[CrossRef][Medline] [Order article via Infotrieve] |
51. | Yoshitome, S., Furuno, N., and Sagata, N. (1998) Biol. Cell 90, 509-518[CrossRef][Medline] [Order article via Infotrieve] |